Literature DB >> 10833096

Gastric permeability to sucrose is increased in portal hypertensive gastropathy.

M R Giofré1, G Meduri, S Pallio, S Calandra, A Magnano, D Niceforo, M Cinquegrani, V di Leo, E Mazzon, G C Sturniolo, G Longo, W Fries.   

Abstract

BACKGROUND: Portal hypertensive gastropathy (PHG) is frequently found among patients with hepatic cirrhosis and at present the only way to detect and follow PHG is via endoscopy.
OBJECTIVE: To assess gastric and intestinal permeability and investigate its relationship to endoscopic findings and indices of portal hypertension and hepatic function. DESIGN AND METHODS: Thirty-one non-diabetic patients with hepatic cirrhosis and PHG (PHG+) were studied and compared with 17 cirrhotic patients without PHG (PHG-). All patients underwent endoscopy for the assessment of PHG and Helicobacter pylori status, ultrasound determination of the diameters of spleen and portal vein, and, subsequently, an oral load of sucrose, lactulose, and mannitol. Sugar concentrations were determined in 6-h urine specimens and expressed as a percentage of the orally administered dose or as lactulose/mannitol ratio.
RESULTS: The urinary sucrose excretion was significantly elevated in patients with PHG compared to those without (PHG+, 0.20% +/- 0.03; PHG-, 0.07% +/- 0.01; P< 0.001). No difference was found for the small intestinal probes lactulose and mannitol. Gastric sucrose permeability correlated positively with the endoscopic lesion score (P < 0.001), but not with other parameters of portal hypertension or hepatic function. H. pylori status did not influence gastric permeability. The sensitivity of this test reached 100% for PHG scores > 2.
CONCLUSIONS: Gastric permeability to sucrose is increased in patients with PHG, independently of the presence of H. pylori. Sucrose permeability may be useful for the follow-up of patients with PHG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833096     DOI: 10.1097/00042737-200012050-00009

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis.

Authors:  Jane Macnaughtan; Rajiv Jalan
Journal:  Am J Gastroenterol       Date:  2015-09-29       Impact factor: 10.864

3.  Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?

Authors:  Tae Wan Kim; Hong Joo Kim; Chang Uk Chon; Hyun Sun Won; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Clin Mol Hepatol       Date:  2012-06-26

Review 4.  Intestinal permeability in a patient with liver cirrhosis.

Authors:  Jonathan Manuel Aguirre Valadez; Liliana Rivera-Espinosa; Osvely Méndez-Guerrero; Juan Luis Chávez-Pacheco; Ignacio García Juárez; Aldo Torre
Journal:  Ther Clin Risk Manag       Date:  2016-11-18       Impact factor: 2.423

5.  A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients.

Authors:  Jane Macnaughtan; Francesco Figorilli; Elisabet García-López; Haw Lu; Helen Jones; Rohit Sawhney; Kaori Suzuki; Sarah Fairclough; Joanne Marsden; Alba Moratella; I Jane Cox; Linda Thomas; Nathan Davies; Roger Williams; Raj Mookerjee; Gavin Wright; Rajiv Jalan
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

6.  NMR spectroscopy enables simultaneous quantification of carbohydrates for diagnosis of intestinal and gastric permeability.

Authors:  Sarah Stryeck; Angela Horvath; Bettina Leber; Vanessa Stadlbauer; Tobias Madl
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

7.  Plasma Metabolites Associated with Coffee Consumption: A Metabolomic Approach within the PREDIMED Study.

Authors:  Christopher Papandreou; Pablo Hernández-Alonso; Mònica Bulló; Miguel Ruiz-Canela; Edward Yu; Marta Guasch-Ferré; Estefanía Toledo; Courtney Dennis; Amy Deik; Clary Clish; Cristina Razquin; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Fernando Arós; Miquel Fiol; José Lapetra; Cristina Ruano; Liming Liang; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó
Journal:  Nutrients       Date:  2019-05-08       Impact factor: 5.717

8.  Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis.

Authors:  Chang Seok Bang; Hyo Sun Kim; Ki Tae Suk; Sung Eun Kim; Ji Won Park; Seung Ha Park; Hyoung Su Kim; Myoung Kuk Jang; Sang Hoon Park; Myung Seok Lee; Choong Kee Park; Dong Joon Kim
Journal:  BMC Gastroenterol       Date:  2016-08-12       Impact factor: 3.067

Review 9.  Gut-liver axis signaling in portal hypertension.

Authors:  Benedikt Simbrunner; Mattias Mandorfer; Michael Trauner; Thomas Reiberger
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.